The International Microbiome Centre (IMC) Mass Cytometry platform in partnership with the Nicole Perkins Microbial Communities Lab is a core facility specializing in high parameter single cell analysis using the CyTOF Helios technology.
Our vision is to use mass cytometry to harness the power of the microbiome for better living.
Our mission is to employ mass cytometry in microbiome research to gain a detailed understanding of host microbial interactions in health and disease. In alignment with the overall IMC mission, the mass cytometry platform also offers the latest cutting-edge technologies for advancement of microbiome research to a broad audience of researchers (internal and external), industry and government including animal health, agriculture, energy and the environment. We promote standardization of mass cytometry protocols and are developing a global network for development of collaborations and partnerships to further enable translation of microbiome research.
Key Areas of Research
Microbiome & Chronic disease
Inflammatory bowel disease
Type 1 Diabetes
Cancer and cancer immuno-therapies
Early life immune education
Sepsis and intensive care medicine
Antibody panel design (human and mouse)
Antibody labelling for mass cytometry
Acquisition of samples
Data analysis support by IMC bioinformatics platform
Dr. Markus Geuking, PhD, Theme Lead, Mass Cytometry, International Microbiome Centre
Markus Geuking, PhD is an Assistant Professor in the Snyder Institute for Chronic Diseases and the Department of Microbiology, Immunology & Infectious Diseases at the University of Calgary. He obtained his PhD at the Swiss Federal Institute for Technology in the lab of Nobel Prize Laureate Prof. Rolf Zinkernagel in Zurich, Switzerland. Subsequently he performed research at McMaster University in Hamilton as a postdoctoral fellow and at the University of Bern (Switzerland) as a research associate
before being recruited to the University of Calgary in 2016. He is a mucosal immunologist and his research team studies how the large number of beneficial bacteria within our intestines, that collectively form the intestinal microbiome, interact and shape our immune system in health and disease.